Relief Therapeutics Expands Its Board Of Directors With The Appointment Of Michelle Lock

0 36

Michelle Lock, Chief Operating Officer of Covis Pharma Group, has been appointed to the Board of Directors of RELIEF THERAPEUTICS Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, as approved and reported after the company’s extraordinary general meeting on January 28, 2022. Relief now has five members on its Board of Directors.

“Michelle’s deep strategic, operational, and commercialization experience, at both big Pharma and emerging biotechnology companies, globally, will be an important addition to our Board, especially as we enter our next stage of company growth. In particular, we look forward to leveraging Michelle’s breadth of expertise and industry relationships garnered from her tenures at Acceleron Pharma, Sage Therapeutics and Bristol-Myers Squibb, as we advance our pipeline including, RLF-100 for acute and chronic lung diseases, the prospective launch of ACER-001 to treat Urea Cycle Disorders later this year, and the expansion of the flagship PKU GOLIKE marketed product line for management of patients with phenylketonuria,”

stated Raghuram (Ram) Selvaraju, Chairman of Relief. 

“Relief’s suite of commercial-stage biopharmaceuticals, along with an impressive product pipeline and highly focused growth strategy, was instrumental in my decision to join the company’s Board. I am delighted to contribute my insights and experience to Relief to help management achieve its U.S. and international commercialization goals at this pivotal time in the company’s history,”  

noted Ms. Lock.

Ms. Lock has approximately 30 years of expertise in the biopharmaceutical sector, including leading roles in commercialization in cancer, hematology, cardiovascular and metabolic illness, liver disease, immunology, virology, and neuroscience. She has also managed pre-launch and launch commercial efforts in a variety of geographies, including the United States, Europe, Japan, Australia, Asia, and emerging markets.

Ms. Lock was recently named Chief Operating Officer of Covis Pharma Group, a global specialty pharmaceutical firm based in Zug, Switzerland that markets therapeutic treatments for patients suffering from life-threatening disorders and chronic illnesses. Ms. Lock previously worked at Acceleron Pharma Inc as to the Senior Vice President and Head of Europe and International, a biopharmaceutical firm focused on the research, development, and commercialization of therapies to treat serious and rare diseases. Prior to that, she worked as a consultant for biotechnology companies, giving leadership, direction, and strategic support to executives looking to start or expand their international operations in Switzerland.

Ms. Lock previously served as Senior Vice President and Head of Europe/International at Sage Therapeutics, a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel medicines to improve the lives of patients suffering from life-threatening central nervous system disorders. Ms. Lock also worked with Bristol-Myers Squibb (BMS) for 24 years, rising through the ranks of sales, commercial, general management, regional leadership, and business strategy. She was most recently Vice President and General Manager for EU Country Clusters & Global Capabilities Hub Leadership, Switzerland, at BMS, where she was responsible for the company’s immuno-oncology leadership activities.

Ms. Lock studied General Management and Internal General Management at CEDEP in France after earning a degree in Science/Nursing from Royal Melbourne University in Australia. She is a past member of the Board of Directors of the Swiss American Chamber of Commerce and the Interpharma Switzerland Pharmaceutical Industry and has served as Honorary Ambassador between Switzerland and the United States since 2018.

Leave A Reply

Your email address will not be published.